BridgeMD
New treatment option for Smokers
Official title A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
ClinicalTrials.gov ID: NCT07058974
What this study is testing
What is lamivudine?
lamivudine is an investigational medicine, being studied as a potential treatment for smokers.
Also referred to as Epivir.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 to 80
You may be able to join if
- Patients 65-80 years old
- Current or former smokers
- BMI 25-32
- No cancer requiring active therapy within the last 2 years
- No autoimmune disease requiring disease modifying agents
You likely can't join if
- Patients may not have cancer requiring active therapy within the last 2 years
- Patients may not have autoimmune disease requiring disease modifying agents
- Patients may not be receiving immune modifying biologic therapies
- Patients may not have chronic kidney disease stage 3/4 or end stage renal disease
- Patients may not have a known history of metabolic dysfunction-associated steatohepatitis
- Patients may not have a known chronic viral infection such as HIV or active Hepatitis B or C, or a known history of genital HSV. Patients who have...
See the full eligibility criteria
- Patients 65-80 years old
- Current or former smokers
- BMI 25-32
- No cancer requiring active therapy within the last 2 years
- No autoimmune disease requiring disease modifying agents
- No patients with CKD stage 3/4 or ESRD
- No class 3 or 4 heart failure
- Patients may not have cancer requiring active therapy within the last 2 years
- Patients may not have autoimmune disease requiring disease modifying agents
- Patients may not be receiving immune modifying biologic therapies
- Patients may not have chronic kidney disease stage 3/4 or end stage renal disease
- Patients may not have a known history of metabolic dysfunction-associated steatohepatitis
- Patients may not have a known chronic viral infection such as HIV or active Hepatitis B or C, or a known history of genital HSV. Patients who have spontaneously or through treatment cleared hepatitis B or C are...
- Patients may not have class 3 or 4 heart failure, or have experienced a myocardial infarction or cerebrovascular event in the past 6 months
- Patients may not have uncontrolled diabetes mellitus
- Patients may not have a history of clinically significant interstitial lung disease (ILD).
- Patients may not have clinically significant active wound healing due to recent injury or surgery
- Patients may not have signs or symptoms of clinically significant acute infectious illness on screening laboratory testing or physical examination.
- Patients may not have evidence of active or latent tuberculosis
- Patients may not have nephrotic range proteinuria on screening labs
- Patients may not have received a live virus within one month of study initiation.
- Patients cannot have uncontrolled hypertension (persistent systolic \>160; diastolic \>100)
- Patients with an inherited primary immunodeficiency
- Patients may not have a history of, or current evidence of, clinically significant chronic liver disease
- Patients may not be receiving any chronic immunosuppressive therapy.
- Patients may not be receiving medications that could increase rapamycin blood concentrations, such as strong inhibitors and inducers of CYP3A4 and/or P-gp (ketoconazole, voriconazole, itraconazole, erythromycin...
- Patients may not be receiving medications that could decrease rapamycin blood concentrations, such as: carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort. Furthermore, these medications may not be...
- Patients may not be receiving medications known to cause angioedema with concomitant use of rapamycin, such as angiotensin-converting enzyme (ACE) inhibitors. Furthermore, these medications may not be used during the...
The study team makes the final eligibility decision.
Where it's taking place
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New York, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.